| 0.0475 -0.022 (-31.16%) | 09-06 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Clarus Therapeutics Holdings, Inc., an Illinois-based pharmaceutical enterprise established in 2003, primarily concentrates on the creation and commercialization of oral testosterone replacement therapies across the United States. Its key offering, JATENZO, is a soft gel oral formulation of testosterone undecanoate designed for managing hypogonadism in men. The company also maintains strategic licensing agreements: one with HavaH Therapeutics for androgenic treatments aimed at inflammatory breast disease and specific forms of breast cancer, and another with The Royal Institution for the Advancement of Learning/McGill University to advance proprietary technology for addressing CoQ10 deficiencies.
Mon, 05 Sep 2022
Clarus Therapeutics Holdings, Inc. Announces Plan for - GlobeNewswire
Mon, 30 May 2022
Clarus Therapeutics Holdings Inc. (CRXT) Share Price Today | Clarus Therapeutics Holdings (CRXT) Live NSE/BSE - Value Research
Mon, 25 Apr 2022
This Weeks Outlook 4/25 - 4/29 - Moomoo
Sun, 17 Apr 2022
Can The FED Save the Bond Market - Moomoo
Thu, 24 Feb 2022
Clarus Announces Strategic Partnerships for JATENZO® - GlobeNewswire
Thu, 14 Oct 2021
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|